Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 65, Issue 1, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01422-20
Keywords
tuberculosis; diabetes; metformin; host-directed
Categories
Funding
- National Health and Medical Research Council (NHMRC) through a CJ Martin Biomedical Early Career Fellowship [APP1052764, APP1140709, APP1120808]
- Australian Institute of Tropical Health and Medicine (AITHM) Capacity Building Grant [15031]
- AITHM scholarship
Ask authors/readers for more resources
There is a difference in the efficacy of MET against tuberculosis in diabetic and nondiabetic individuals, which warrants further investigation.
Comorbid type 2 diabetes poses a great challenge to the global control of tuberculosis. Here, we assessed the efficacy of metformin (MET), an antidiabetic drug, in mice infected with a very low dose of Mycobacterium tuberculosis. In contrast to diabetic mice, infected nondiabetic mice that received the same therapeutic concentration of MET presented with significantly higher disease burden. This warrants further studies to investigate the disparate efficacy of MET against tuberculosis in diabetic and nondiabetic individuals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
